Biomarker IDs cancer patients most likely to respond to EGFR inhibitors

A team of scientists at A*STAR's Institute of Molecular and Cell Biology say they've identified a particular biomarker which can be used to identify how patients will likely respond to EGFR inhibitors. They noted that cancer cells with elevated levels of PRL-3 are more rapidly destroyed by EGFR inhibitors, making them prime candidates for therapy. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.